Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bare Metal Stents and Drug Eluting Stents Are Segments under the Coronary Stents Umbrella inside Global Report For 2006.


DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c41179) has announced the addition of Coronary Stents - Global Strategic Business Report to their offering.

This report analyzes the worldwide markets for Coronary Stents in US$ Million. The major product segments analyzed are Bare Metal 1. bare metal - New computer hardware, unadorned with such snares and delusions as an operating system, an HLL, or even assembler. Commonly used in the phrase "programming on the bare metal", which refers to the arduous work of bit bashing needed to create these basic tools  Stents, and Drug Eluting Stents. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2001 through 2010. The report profiles 49 companies including many key and niche players worldwide.

Contents Include:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II.

1. Global Market Overview

2. Market Trends and Issues

3. Competitive Analysis

4. Product Overview

5. Product Segments

6. Research and Development

7. Product Introductions

8. Product Launches in the Recent Past

9. Recent Industry Activity

10. Strategic Corporate Developments in Past

11. Focus on Select Players

12. Global Market Perspective

III. MARKET

1. United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area.  

2. Japan

3. Europe

4. Asia-Pacific

5. Rest of World

IV. COMPETITION

Some Companies Mentioned include:

Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois.  (USA)

Angiotech Pharmaceuticals Angiotech TSX: ANP is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. , Inc (Canada)

Atrium Medical Corporation (USA)

AVI Biopharma AVI BioPharma Inc. is a medical research and drug development company with corporate offices in Portland, Oregon, United States, and laboratories in Corvallis, Oregon. It was incorporated in 1980. , Inc (USA)

B Braun Melsungen AG (Germany)

Biocompatibles UK Ltd (UK)

Biotronik GmbH & Co (Germany)

Biotronik, Inc (USA)

Biotronik UK Ltd (UK)

Blue Membranes GmbH (Germany)

Bolton Medical, Inc (USA)

Boston Scientific The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions,  Corporation (USA)

Guidant Corporation (USA)

Guidant (Canada)

Brittan Healthcare (Pty) Ltd (South Africa)

CardioTech International, Inc (USA)

ClearStream Technologies Limited (Ireland)

Conor Medsystems, Inc (USA)

Cook Group, Inc (USA)

Debiotech SA (Switzerland)

Devax, Inc (USA)

Disa Vascular (Pty) Ltd (South Africa)

Endologix, Inc (USA)

Endovasc, Inc (USA)

Eucatech AG (Germany)

EuroCOR GmbH (Germany)

EV, INC (USA)

Goodman Co, Ltd (Japan)

Avantec Vascular Corporation (USA)

Hexacath (France)

Implant Sciences Corporation (USA)

Insitu Technologies, Inc (USA)

Johnson & Johnson (USA)

Cordis Corporation (USA)

Cordis Europa NV (The Netherlands)

Medinol Ltd (Israel)

MediVas LLC (Logical Link Control) See "LANs" under data link protocol.

LLC - Logical Link Control
 (USA)

Medtronic, Inc (USA)

Medtronic Vascular Division (USA)

MIV MIV Motorisierter Individualverkehr (German: Motorized Individual Traffic)
MIV Master Internet Volunteer (University of Minnesota Extension Service)
MIV Multimedia, Internet & Video
 Therapeutics, Inc (Canada)

Novartis Pharma Switzerland AG (Switzerland)

Novoste Corporation (USA)

Orbusneich (Hong Kong)

Relisys Medical Devices (India)

Sahajanand Medical Technologies (India)

Shenzhen Lifetech Scientific, Inc (China)

Shiga Medical Center (Japan)

Snia SpA (Italy)

Sorin Biomedica Cardio SpA (Italy)

Sun Biomedical bi·o·med·i·cal
adj.
1. Of or relating to biomedicine.

2. Of, relating to, or involving biological, medical, and physical sciences.
 Ltd (USA)

Biosensors International Pte, Ltd (Singapore)

Occam International BV (The Netherlands)

SurModics, Inc (USA)

For more information visit http://www.researchandmarkets.com/reports/c41179
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 25, 2006
Words:383
Previous Article:Company Profile for Oil States Trading.
Next Article:Company Profile for Pacific Financial Printing.
Topics:



Related Articles
Things just mesh: making stents even better at keeping arteries open.
TAKING AIM AT CLOGGED ARTERIES AV HOSPITAL OFFERING NEW BREAKTHROUGH.
Coated inserts keep vessels unclogged.
AVI BIOPHARMA INITIATES PHASE II CARDIOVASCULAR CLINICAL STUDY.
Stent repair: coated replacements better than radiation.
Women & heart health: from prevention to intervention.
Analysis of the Leading Players within the Drug Eluting Stents Market.
AVI BioPharma Provides Cardiovascular Program Update; Notice of Allowance of Two Patents Strengthens Cardiovascular Restenosis Program.
Clinical Data Reveals Bare-Metal Stents May Be More Effective Than Predicted; New Study Shows Less than 8 Percent of Patients Need Follow-up...
New Safety Concerns Have Begun to Erode the Market Share of Drug-Eluting Stents.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles